Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pelthos Therapeutics ( (PTHS) ) has shared an update.
On October 14, 2025, Pelthos Therapeutics announced a presentation detailing the commercial launch of Zelsuvmi, a groundbreaking treatment for Molluscum contagiosum. This launch positions Pelthos as a leader in addressing this widespread condition, with Zelsuvmi offering a convenient at-home treatment option, potentially capturing a significant share of a $20 billion market.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics is a bio-pharmaceutical company focused on commercializing innovative therapeutic products to address unmet treatment needs. The company recently launched Zelsuvmi, the first at-home treatment for Molluscum contagiosum, a contagious viral disease affecting millions, with a significant market opportunity.
Average Trading Volume: 13,381
Technical Sentiment Signal: Strong Buy
See more insights into PTHS stock on TipRanks’ Stock Analysis page.